Viking Therapeutics (NASDAQ:VKTX – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a research report issued on Friday.
A number of other analysts have also recently issued reports on VKTX. Roth Capital reiterated a “buy” rating on shares of Viking Therapeutics in a research note on Tuesday, May 30th. Raymond James lifted their price target on shares of Viking Therapeutics from $35.00 to $37.00 in a research report on Wednesday, May 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $30.00 price target on shares of Viking Therapeutics in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.25.
Viking Therapeutics Trading Up 8.8 %
NASDAQ VKTX traded up $1.28 during trading on Friday, reaching $15.89. The company’s stock had a trading volume of 2,866,538 shares, compared to its average volume of 3,128,129. The stock has a market capitalization of $1.59 billion, a PE ratio of -17.46 and a beta of 0.52. The business has a 50-day moving average price of $14.63 and a 200-day moving average price of $16.80. Viking Therapeutics has a 1-year low of $2.53 and a 1-year high of $25.72.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last posted its earnings results on Wednesday, July 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Viking Therapeutics’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.23) earnings per share. As a group, analysts expect that Viking Therapeutics will post -0.91 earnings per share for the current year.
Hedge Funds Weigh In On Viking Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of VKTX. Retirement Group LLC increased its holdings in Viking Therapeutics by 75.0% in the 2nd quarter. Retirement Group LLC now owns 2,100 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 900 shares during the period. Cetera Advisor Networks LLC bought a new stake in Viking Therapeutics in the 2nd quarter valued at $36,000. Engineers Gate Manager LP bought a new stake in Viking Therapeutics in the 1st quarter valued at $37,000. Allspring Global Investments Holdings LLC bought a new stake in Viking Therapeutics in the 2nd quarter valued at $48,000. Finally, Envestnet Asset Management Inc. bought a new stake in Viking Therapeutics in the 2nd quarter valued at $53,000. Institutional investors own 78.13% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.